5% Off
Perjeta420 mg/14
Roche Bangladesh Ltd.
৳166250.00
Out Of Stock
Generic medicine
Pertuzumab: Brands, Price & Uses in Bangladesh
Pertuzumab is a HER2-targeted monoclonal antibody approved only for use in combination regimens for HER2-positive breast cancer and more.
About Pertuzumab
Indications of Pertuzumab
Pertuzumab is a HER2-targeted monoclonal antibody approved only for use in combination regimens for HER2-positive breast cancer, based on confirmed HER2 overexpression/gene amplification by an FDA-approved test. It is not used as monotherapy.
Established (FDA-approved) indications
| Setting | Combination | Patient population |
|---|---|---|
| Neoadjuvant (before surgery) | With trastuzumab and chemotherapy | HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (tumor greater than 2 cm or node-positive), as part of a complete treatment regimen |
| Adjuvant (after surgery) | With trastuzumab and chemotherapy | HER2-positive early breast cancer at high risk of recurrence |
| Metastatic | With trastuzumab and docetaxel | HER2-positive metastatic breast cancer in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease |
Pertuzumab is not approved for HER2-negative breast cancer or for cancers other than breast cancer, and is not established as effective outside of these specific combination regimens.
Dosage & Administration of Pertuzumab
Pertuzumab should be used only after confirming HER2 positivity by a validated test, and is always given in combination with trastuzumab and chemotherapy, administered by intravenous infusion under the supervision of a physician experienced in cancer chemotherapy.
Dosing
| Dose | Regimen |
|---|---|
| Initial (loading) dose | 840 mg by IV infusion over 60 minutes |
| Maintenance dose | 420 mg by IV infusion over 30 to 60 minutes, every 3 weeks, together with trastuzumab and chemotherapy, for the number of cycles specified by the approved regimen being used |
Missed or delayed dose
- Less than 6 weeks since the last infusion: give the 420 mg maintenance dose as soon as possible; do not wait for the next scheduled dose.
- 6 weeks or more since the last infusion: re-administer the 840 mg initial dose over 60 minutes, then resume the 420 mg dose every 3 weeks.
Dose modification for cardiac dysfunction
Pertuzumab and trastuzumab are withheld for a significant drop in left ventricular ejection fraction (LVEF) and resumed only if LVEF recovers per protocol criteria. No dose reduction of Pertuzumab is recommended for any indication; a dose is either given in full or withheld.
Side Effects of Pertuzumab
The most common side effects, occurring in more than 30% of patients receiving Pertuzumab-based combination regimens, include:
- Diarrhea
- Alopecia (hair loss)
- Nausea
- Neutropenia (low white blood cell count)
- Fatigue
- Rash
- Peripheral neuropathy
- Vomiting and headache
Serious adverse effects
- Infusion-related reactions, including hypersensitivity or anaphylaxis (see Precautions and Warnings)
- Left ventricular dysfunction, decreased LVEF, or congestive heart failure (see Precautions and Warnings)
- Febrile neutropenia
- Severe diarrhea that may require hospitalization and fluid or electrolyte management
Contraindications of Pertuzumab
Pertuzumab is contraindicated in patients with known hypersensitivity to Pertuzumab or to any of its excipients.
Frequently Asked Questions about Pertuzumab
What is Pertuzumab used for?
Pertuzumab is used, always in combination with trastuzumab and chemotherapy, to treat HER2-positive breast cancer, including certain early-stage cases before or after surgery (neoadjuvant/adjuvant) and metastatic (advanced) disease.
Can Pertuzumab be used alone?
No. Pertuzumab is only approved and effective as part of a combination regimen with trastuzumab and chemotherapy; it is not used as a standalone treatment.
Is Pertuzumab safe during pregnancy?
No. Pertuzumab carries a boxed warning because it can cause serious fetal harm, including fetal death and birth defects. Pregnancy must be ruled out before starting treatment, and effective contraception is required during treatment with Pertuzumab and for at least 7 months afterward. Any suspected pregnancy during treatment should be reported to a physician immediately.
What monitoring is needed while taking Pertuzumab?
Because Pertuzumab, especially combined with trastuzumab, can affect heart function, doctors check heart pumping function (LVEF) before and periodically during treatment. Patients are also observed during and after each infusion of Pertuzumab for infusion-related or allergic reactions, and monitored for diarrhea, which can sometimes be severe.
What are the most common side effects of Pertuzumab?
The most common side effects of Pertuzumab-based treatment include diarrhea, hair loss, nausea, low white blood cell counts, fatigue, and rash. Patients should tell their care team promptly about severe or persistent symptoms.
What happens if a dose of Pertuzumab is missed or delayed?
If less than 6 weeks have passed since the last dose of Pertuzumab, the regular maintenance dose is given as soon as possible. If 6 weeks or more have passed, treatment restarts with the full initial (loading) dose of Pertuzumab before resuming the regular every-3-week schedule. This decision is always made by the treating physician.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.